arrow
N

Nikolas von Bubnoff

University of Schleswig-Holstein
H指数:50
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM

双输血独立性及脾脏体积缩小与接受莫美洛替尼治疗的骨髓纤维化患者总生存期相关:SIMPLIFY-1和MOMENTUM试验的事后分析

2026-10-080
OAAI
Robotic Centrifugal Microfluidics with In-Rotation Liquid Supply for the Extraction of Multiple Liquid Biopsy Analytes in One Platform

旋转离心微流控机器人与旋转中液体供给,用于单平台中多种液体活检分析物的提取

2026-05-280
OA
Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1

脾脏体积缩小和输血独立性:比较momelotinib与ruxolitinib,以及momelotinib相关的总生存期,在JAK抑制剂初治伴有贫血的骨髓纤维化患者中的亚组分析:SIMPLIFY-1研究。

2026-05-010
OAAI
Survival outcomes after front-line consolidation with high-dose Melphalan and autologous stem cell transplantation in younger and elderly multiple myeloma patients: a retrospective bi-centric analysis

年轻和老年多发性骨髓瘤患者一线大剂量美法仑联合自体干细胞移植巩固治疗的生存结局:一项回顾性双中心分析

2025-12-150
OAAI
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism

原发性肾弥漫大B细胞淋巴瘤的分子分型揭示了其对免疫特惠部位的嗜性

2025-05-260
OA
Coupling Immunoprecipitation with Multiplexed Digital PCR for Cell-Free DNA Methylation Detection in Small Plasma Volumes of Early-Onset Colorectal Cancer

将免疫沉淀与多重数字PCR联用,用于早期发病结直肠癌小体积血浆中细胞游离DNA甲基化检测

2025-05-170
OA
Molecular profiling of primary renal marginal zone lymphoma reveals overlapping features with extranodal marginal zone lymphoma

原发性肾边缘区淋巴瘤的分子特征分析揭示其与结外边缘区淋巴瘤具有重叠特征

2025-05-130
OA
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases

鲁索利替尼介导的矛盾性JAK2过度磷酸化是由于保护了激活环酪氨酸免受磷酸酶的影响。

LEUKEMIA
IF13.4
2025-04-230
OA
Case report: Tenosynovial giant cell tumor
2024-09-260
OAAI
Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial

Inavolisib在具有激活性PIK3CA突变的癌症中的研究:CRAFT试验的结果

2024-09-010
PRE